Literature DB >> 11431659

Clinical outcome of a cohort of patients eligible for therapeutic angiogenesis or transmyocardial revascularization.

D Mukherjee1, K Comella, D L Bhatt, M T Roe, V Patel, S G Ellis.   

Abstract

BACKGROUND: Newer methods of coronary revascularization are being investigated in patients who are not candidates for coronary artery bypass grafting or percutaneous intervention. Our objective was to determine the proportion of patients eligible for newer methods of revascularization and determine their 1-year clinical outcome.
METHODS: Five hundred consecutive charts and angiograms from patients undergoing diagnostic angiography for coronary artery disease from January to May of 1998 were reviewed to assess the suitability for revascularization. Patients ineligible for conventional revascularization were followed up for 1 year.
RESULTS: Fifty-nine patients of the 500 studied were identified who had refractory ischemia but were not candidates for traditional revascularization. The 59 patients ineligible for traditional methods of revascularization had a rehospitalization rate of 128% (76 total hospitalizations), a 25.5% rate of myocardial infarction (15 of 59), and a mortality rate of 16.9% (10 of 59).
CONCLUSIONS: The prognosis of many patients eligible for newer methods of revascularization on maximal medical therapy is poor.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11431659     DOI: 10.1067/mhj.2001.115786

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  10 in total

Review 1.  Advancements in pharmacotherapy for angina.

Authors:  Ankur Jain; Islam Y Elgendy; Mohammad Al-Ani; Nayan Agarwal; Carl J Pepine
Journal:  Expert Opin Pharmacother       Date:  2017-03-15       Impact factor: 3.889

Review 2.  Current clinical perspectives on myocardial angiogenesis.

Authors:  Debabrata Mukherjee
Journal:  Mol Cell Biochem       Date:  2004-09       Impact factor: 3.396

Review 3.  Contemporary Management of Refractory Angina.

Authors:  Rebekah Lantz; Odayme Quesada; Georgia Mattingly; Timothy D Henry
Journal:  Interv Cardiol Clin       Date:  2022-07

4.  A prospective study of patients with refractory angina: outcomes and the role of high-sensitivity troponin T.

Authors:  Nilson T Poppi; Luís H W Gowdak; Luciana O C Dourado; Eduardo L Adam; Thiago N P Leite; Bruno M Mioto; José E Krieger; Luiz A M César; Alexandre C Pereira
Journal:  Clin Cardiol       Date:  2016-10-18       Impact factor: 2.882

Review 5.  Treatment of refractory angina in patients not suitable for revascularization.

Authors:  Timothy D Henry; Daniel Satran; E Marc Jolicoeur
Journal:  Nat Rev Cardiol       Date:  2013-12-24       Impact factor: 32.419

6.  Testing clinical therapeutic angiogenesis using basic fibroblast growth factor (FGF-2).

Authors:  Ronnier J Aviles; Brian H Annex; Robert J Lederman
Journal:  Br J Pharmacol       Date:  2003-10       Impact factor: 8.739

Review 7.  Protein-, gene-, and cell-based therapeutic angiogenesis for the treatment of myocardial ischemia.

Authors:  Marc Ruel; Jianming Song; Frank W Sellke
Journal:  Mol Cell Biochem       Date:  2004-09       Impact factor: 3.396

8.  Predictors of long-term clinical endpoints in patients with refractory angina.

Authors:  Thomas J Povsic; Samuel Broderick; Kevin J Anstrom; Linda K Shaw; E Magnus Ohman; Eric L Eisenstein; Peter K Smith; John H Alexander
Journal:  J Am Heart Assoc       Date:  2015-01-30       Impact factor: 5.501

9.  Percutaneous Device to Narrow the Coronary Sinus: Shifting Paradigm in the Treatment of Refractory Angina? A Review of the Literature.

Authors:  Daniela Benedetto; Masieh Abawi; Pieter R Stella; Freek Nijhoff; Maxime D M Lakemeier; Friso Kortlandt; Pieter A Doevendans; Pierfrancesco Agostoni
Journal:  Front Cardiovasc Med       Date:  2016-10-21

10.  Repetitive myocardial ischemia promotes coronary growth in the adult mammalian heart.

Authors:  Kory J Lavine; Attila Kovacs; Carla Weinheimer; Douglas L Mann
Journal:  J Am Heart Assoc       Date:  2013-09-30       Impact factor: 5.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.